Boswellin® HBD

HomeBoswellin® gradesBoswellin® HBD

Boswellin® HBD (D.C) is obtained from the gum exudate of Boswellia serrata trees commonly known as Frankincense.

Boswellin® HBD is standardized to contain:

Total boswellic acids by titration 70.0%- 85.0% w/w
ß-boswellic acids 20.0%- 30.0% w/w
AKBA 2.0% w/w (MIN)

Salient features

  • 100% natural
  • No preservatives
  • Established safety

Efficacy of Boswellin® HBD

Pre-clinical studies
Anti-inflammatory/Anti-arthritic effects
Active components of Boswellin® HBD exert a synergistic effect

The actives, BBA and AKBBA, act synergistically to exert anti‐inflammatory activity efficaciously in reducing joint pain and improving the physical functional ability in patients with osteoarthritis (OA) of knee33.

Boswellin
R1= H; R2= H: BBA
R1= COCH3; R2= H: ABBA
R1= H; R2,R2= O: KBBA
R1= COCH3; R2,R2= O: AKBBA
Anti-inflammatory/Anti-arthritic action
Inhibition
Cytokines (inflammatory interleukins: IL-1β, IL-6, IL-15 & IL-17) and TNF-αBBA
Reactive oxygen species (ROS)BBA, AKBBA
Lipopolysacharide (LPS)BBA
Nuclear factor-kB (NF-kB)BBA, AKBBA
Human leukocyte elastase (HLE)BBA, AKBBA
5-Lipoxygenase(5-LOX)BBA, AKBBA
High-sensitivity c-reactive proteins
(hs-CRP)		BBA, AKBBA
Microsomal prostaglandin e synthase-1 (mPGES-1)BBA
Prostaglandin E2(PGE2)BBA
Cathepsin (CatG)BBA, AKBBA
Activation
Endothelial NOS (eNOS)/ Nitric oxide (NO)/ Cyclic guanosine 3', 5'-monophosphate (cGMP) pathwaysBBA
Boswellin
R1= H; R2= H: BBA
R1= COCH3; R2= H: ABBA
R1= H; R2,R2= O: KBBA
R1= COCH3; R2,R2= O: AKBBA
Anti-inflammatory/Anti-arthritic action
Inhibition
Cytokines (inflammatory interleukins: IL-1β, IL-6, IL-15 & IL-17) and TNF-αBBA
Reactive Oxygen Species (ROS)BBA, AKBBA
Lipopolysacharide (LPS)BBA
Nuclear factor-kB (NF-kB)BBA, AKBBA
Human leukocyte elastase (HLE)BBA, AKBBA
5-Lipoxygenase(5-LOX)BBA, AKBBA
High-sensitivity C-reactive proteins
(hs-CRP)		BBA, AKBBA
microsomal Prostaglandin E Synthase-1 (mPGES-1)BBA
Prostaglandin E2(PGE2)BBA
Cathepsin (CatG)BBA, AKBBA
Activation
Endothelial NOS (eNOS)/ nitric oxide (NO)/ cyclic guanosine 3', 5'-monophosphate (cGMP) PathwaysBBA

Anti-inflammtory/Anti-arthritic action

β‐boswellic acid (BBA)

3‐acetyl‐11‐keto‐β‐boswellic acid (AKBBA)

Interleukin (IL)

11‐keto‐β‐boswellic acid (KBBA)

Tumor necrosis factor alpha (TNF‐α)

Anticancer effects
In hepatic cancer cells (Hep G2) treated with KBA and AKBA37
  • Both KBA and AKBA induced apoptosis
  • Increased activity of caspase-8 (the initiator of apoptosis) as well as caspase-3 (the executor of apoptosis)
  • Released DNA-histone complex in to the cell cytoplasm
  • Increased percentage of cells in the sub-Gl phase by checking in G1 phase